Alectinib — Drug Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

6 Recruiting

5 Completed trials

7 Sponsors

19 Countries

Phase III

Phase II

Phase III: 4 Phase II: 7 Phase IV: 1

Oversight events:

1 serious breach 1 urgent safety measure across 2 trials

View oversight register →

Indications tested

Non-small cell lung cancer 4 Squamous cell carcinoma of head and neck 1 Anaplastic lymphoma kinase gene mutation 1 Non-small cell lung cancer stage IV 1 Skin cancer 1 Non-small cell lung cancer stage III 1 Renal cell carcinoma 1 Triple negative breast cancer 1 Colorectal cancer metastatic 1 Ovarian cancer 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 6 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 1 G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica 1 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 HUS-Yhtymae 1 Oslo University Hospital HF 1 Universitair Medisch Centrum Groningen 1

All trials

12 total

Phase II, open label, single arm, multicenter study to assess the activity and safety of ALectinib as NE O adjuvant therapy in patients with… Pending

2024-519106-12-00 Phase II 1 country G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica
A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on the… Recruiting

2024-511239-91-00 Phase II 8 countries F. Hoffmann-La Roche AG
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N… Recruiting

2023-503920-14-00 Phase III 9 countries F. Hoffmann-La Roche AG
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC) Recruiting

2023-506886-76-00 Phase IV 2 countries Universitair Medisch Centrum Groningen
FINPROVE - The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Recruiting

2024-517478-68-01 Phase II 1 country HUS-Yhtymae
EVIDENT Recruiting

2023-510092-62-00 Phase II 1 country Oslo University Hospital HF
DRUP trial Recruiting

2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended

2023-507418-28-00 Phase II 8 countries F. Hoffmann-La Roche AG
An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizu… Ended

2023-506184-34-00 Phase III 11 countries F. Hoffmann-La Roche AG
A Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Re… Ended

2023-506861-76-00 Phase III 10 countries F. Hoffmann-La Roche AG
ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive nonsmall cell lung cancer (ALK+ NSCLC) patients by deep phenoty… Ended

2024-513947-94-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Parti… Ended

2023-506859-13-00 Phase III 4 countries F. Hoffmann-La Roche AG

Showing 1–12 of 12 trials

← All drugs A–Z